There is an increasing evidence for genetic contribution to Parkinson's disease (PD). Genes responsible for monogenetic hereditary PD have been discovered to carry less devastating mutations associated with "idiopathic" PD, suggesting that common molecular pathways are involved in the pathogenesis of monogenetic and "idiopathic" PD. Recently, genome wide association studies (GWAS) have revealed new PARK loci, potentially harboring genes conferring an increased or decreased risk of developing PD. We have studied PARK18, for which HLA-DRA, a class II human leukocyte antigen, was proposed as a candidate gene. Hamza et al. [1] reported that the G allele of the single nucleotide polymorphism (SNP) rs3129882 (A/G) in HLA-DRA, associates with increased risk for PD in an American cohort. Attempts to replicate the association have shown conflicting results [2] [3] [4] [5] ; not only were there lack of associations in several cohorts [2] [3] [4] [5] , but the GG genotype has also been found to be protective [3] . Variable findings in different studies point to the presence of geographical and ethnical differences and hence the importance of validating GWAS findings in independent homogenous case-control materials. We have performed a replication study on the HLA-DRA SNP rs3129882 in a homogenous Swedish case-control material in order to further investigate the possible contribution of rs3129882 to PD.
Blood samples were collected at the Karolinska and Linköping University Hospitals after informed consent and approval of the Regional Ethical Review Board. DNA was obtained from samples using standard protocols. We genotyped rs3129882 in 511 PD patients and 636 neurologically healthy controls (Table 1) . A subset of the patients (172) and controls (279) from Linköping was previously genotyped for rs3129882 in another study [5] . Control individuals were neurologically healthy spouses of patients (4%), individuals visiting hospitals for non-neurological disorders (54%) and from the SNAC-K project (The Swedish National Study on Aging and Care in Kungsholmen http://www.snac-k.se/) (42%). All samples are unrelated Caucasians from urban areas from the rather small population of Sweden, likely to represent a homogenous case-control material. Genotyping was performed by real-time polymerase chain reaction (PCR) (7500 fast system using standard cycling conditions, TaqMan Ò genotyping master mix and Genotyping Assay C_2455644_10, Applied
Biosystems/Life Technologies, Carlsbad, California, USA). Due to a non-negligible level of heterogeneity in the read-out in a subset of the Linköping samples with lower DNA concentration, these samples were re-sequenced with the pyrosequencing technique to confirm genotyping results. A PCR was run with Taq polymerase enzyme and two primers, one of which was biotinylated at the 5 0 end (Thermo Fisher Scientific, Ulm, Germany), (sequences are available upon request). The PCR product was purified according to manufacturer's instructions, incubated with a sequencing primer and analyzed by PYRO-sequencing (PSQ 96MA system, BIOTAGE AB Uppsala, Sweden) using PyroMark Gold Q96 Reagents (QIAGEN AB, Solna, Sweden). Three PD patients were excluded from the analysis since they were carriers of the pathogenic G2019S mutation LRRK2. Association was evaluated with Chi-square (c 2 ) and Fisher's exact test, significance level 5%, two-sided P-values (GraphPad Prism 5.03, GraphPad Software, San Diego California USA). Power and sample size software PS 3.0 was used for power analysis (http://biostat.mc.vanderbilt.edu/ wiki/Main/PowerSampleSize). With our sample size we can detect an odds ratio of <0.712 and >1.390 with a power of 80% (a ¼ 0.05).
We genotyped a total of 511 PD patients and 636 neurologically healthy controls from Sweden and searched for possible genotypic and allelic association between rs3129882 and PD. Rs3129882 was in Hardy Weinberg equilibrium for all subjects (data not shown). We first analyzed the entire material for which we found no genotypic (data not shown) or allelic association for rs3129882 and PD (Table 2 ). In order to investigate variability in subgroups of patients, we stratified the material with respect to age of onset, 
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sex and self-reported family history. Female and male patients were compared to the whole control group since genotype and allele frequencies were similar in the control groups (P > 0.5). Patients with maximum one first-, second-or third-degree relative were included in the group designated as having no known heredity, while familial PD was defined as patients with two or more relatives with PD. Applying these stringent selection criteria corresponding to those used in the report by Hamza et al. [1] , we discovered no further association for rs3129882 with PD (Table 2) . Previous replication studies on HLA-DRA show very heterogeneous results [1] [2] [3] [4] [5] . These variations might be explained by ancestry; allele frequencies for rs3129882 vary greatly in different geographical regions. Hamza et al. [1] reported a significant substructure in American subjects of European decent correlating with the country of origin of the subjects' ancestors. Association was stronger in subjects with ancestors from Northern Europe. However, no replication has yet been reported in European cohorts. We found no association in our exclusively Swedish material which is in agreement with recent findings in a Scandinavian (Sweden, Norway) population [5] . According to Hamza et al. [1] , association was stronger in sporadic PD patients with late onset. To mimic their study we performed an age of onset stratified analysis, but failed to detect any further significant differences. Therefore, our results do not suggest a role for HLA-DRA variants for PD in Sweden. Variable results in genetic replication studies can also be explained by different Linkage Disequilibrium (LD). Association can be found with an SNP which is in LD with the true disease causing SNP, while in another population these two SNPs are not in LD. HLA genes, being closely located on chromosome 6, could exert a joint effect. Rs3129882 is for example believed to influence expression levels of HLA-DRA, HLA-DQA2 and HLA-DRB5 [1] . Published data on HLA-DR associations with PD are so far more in favor of association with HLA-DRB loci, which are also more polymorphic, than with the rather invariable HLA-DRA.
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